Reduced Cytokine Release Syndrome and Improved Outcomes with Earlier Immunosuppressive Therapy in Haploidentical Stem Cell Transplantation

This publication has 28 references indexed in Scilit:

• Post-Transplant High-Dose Cyclophosphamide for the Prevention of Graft-versus-Host Disease
  Transplantation and Cellular Therapy, 2015
• Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation
  Blood, 2015
• HLA Match Likelihoods for Hematopoietic Stem-Cell Grafts in the U.S. Registry
  New England Journal of Medicine, 2014
• Current concepts in the diagnosis and management of cytokine release syndrome
  Blood, 2014
• T-Cell–Replete HLA-Haploidentical Hematopoietic Transplantation for Hematologic Malignancies Using Post-Transplantation Cyclophosphamide Results in Outcomes Equivalent to Those of Contemporaneous HLA-Matched Related and Unrelated Donor Transplantation
  Journal of Clinical Oncology, 2013
• Post-Transplantation Cyclophosphamide for Tolerance Induction in HLA-Haploidentical Bone Marrow Transplantation
  Seminars in Oncology, 2012
• Haploidentical hematopoietic transplantation: current status and future perspectives
  Blood, 2011
• High-dose, post-transplantation cyclophosphamide to promote graft-host tolerance after allogeneic hematopoietic stem cell transplantation
  Immunologic Research, 2010
• HLA-Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Using Nonmyeloablative Conditioning and High-Dose, Posttransplantation Cyclophosphamide
  Transplantation and Cellular Therapy, 2008
• Marrow Transplantation from Related Donors Other Than HLA-Identical Siblings
  New England Journal of Medicine, 1985